# Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients

> **NCT00536575** · PHASE1,PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 13 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT00536575
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2010-02
- **Final completion:** 2010-08
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2013-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00536575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00536575, "Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00536575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*